AP

Alzheimer’s drug shows promise in early results of study

Sep 27, 2022, 6:06 PM | Updated: Sep 28, 2022, 3:00 pm

FILE — The Biogen Inc., headquarters is shown March 11, 2020, in Cambridge, Mass.  Shares of Biog...

FILE — The Biogen Inc., headquarters is shown March 11, 2020, in Cambridge, Mass. Shares of Biogen and other drugmakers researching Alzheimer’s disease soared early Wednesday, Sept. 28, 2022, after Japan’s Eisai Co. said its potential treatment appeared to slow the fatal disease’s progress in a late-stage study. Eisai announced results late Tuesday from a global study of nearly 1,800 people with early-stage Alzheimer’s (AP Photo/Steven Senne, File)

(AP Photo/Steven Senne, File)

Shares of Biogen and other drugmakers researching Alzheimer’s disease soared Wednesday after Japan’s Eisai Co. said its potential treatment appeared to slow the fatal disease in a late-stage study.

The drugmaker said early results showed that its treatment, lecanemab, reduced patient clinical decline by 27% when compared to a placebo or fake drug after 18 months of the infused treatment.

Eisai announced results late Tuesday from a global study of nearly 1,800 people with early-stage Alzheimer’s.

Patients were monitored using a scale that measures mental decline and their ability to do daily activities like getting dressed or feeding oneself.

Eisai Co. Ltd. said it would discuss full results from the research at a conference in late November. It also plans to publish findings in a peer-reviewed medical journal.

The company is already seeking an accelerated approval from the U.S. Food and Drug Administration, and the agency is expected to decide by early next year. Eisai and Biogen will co-promote the drug.

Researchers typically urge caution in evaluating a study until the full results are released. But the initial findings appear to be “quite robust” and will likely support regulatory approval, Mizuho Securities analyst Graig Suvannavejh said in a research note.

A statement from the Alzheimer’s Association called the findings the most encouraging to date for potential treatments of the underlying disease causes.

Some 6 million people in the U.S. and many more worldwide have Alzheimer’s, which gradually attacks areas of the brain needed for memory, reasoning, communication and basic daily tasks.

Alzheimer’s has no known cure. Long-standing treatments on the market just manage symptoms, and researchers don’t fully understand what causes the disease.

Last year, Biogen’s Aduhelm became the first new Alzheimer’s drug introduced in nearly two decades. But it has largely flopped after debuting with a price tag of $56,000 annually, which Biogen later slashed.

Doctors have been hesitant to prescribe it, given weak evidence that the drug slows the progression of Alzheimer’s. Insurers have blocked or restricted coverage due to concerns over the drug’s high price tag and uncertain benefit.

Earlier this year, the federal Medicare program imposed strict limits on who can get the drug, wiping out most of its potential U.S. market. Biogen announced afterward that it would stop most of its spending on the treatment.

Like Aduhelm, lecanemab, which Eisai developed, aims to clear a protein called beta-amyloid from the brain.

The protein forms a plaque that researchers believe is a contributor to Alzheimer’s. They also point to other potential factors like family history and chronic conditions such as diabetes.

Eisai executives say lecanemab focuses more on floating clumps of the protein before it forms the plaque, which is what Aduhelm targets.

Eli Lilly and Co. also is developing a potential treatment, donanemab, that targets the protein.

Shares of Cambridge, Massachusetts-based Biogen Inc. jumped 40% to close Wednesday at $276.61. The stock had largely tumbled since Aduhelm’s debut last year.

Shares of Indianapolis-based Eli Lilly and Co. rose 7.5%.

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

AP

Image: O.J. Simpson attends his parole hearing at Lovelock Correctional Center July 20, 2017 in Lov...

Associated Press

O.J. Simpson, fallen football hero acquitted of murder in ‘trial of the century,’ dies at 76

O.J. Simpson, the former NFL star and Hollywood actor who was acquitted of charges he killed his ex-wife and her friend has died at 76.

2 days ago

Southwest Airlines boeing...

Associated Press

An engine cover on a Southwest Airlines plane rips off, forcing the flight to return to Denver

A Southwest Airlines jet, a Boeing 737, returned to Denver Sunday morning after the engine cover fell off and struck the wing flap during takeoff.

5 days ago

Image: The late Careaga family....

Associated Press

3 found guilty in 2017 quadruple killing of Washington family

A jury has found three men guilty of killing a family in Washington in 2017, crimes detectives asserted happened over drugs and money.

7 days ago

The logo for Boeing appears on a screen above a trading post on the floor of the New York Stock Exc...

Associated Press

Boeing’s CEO got compensation worth nearly $33M last year but lost a $3M bonus

Boeing's CEO got around $33 million in compensation, nearly all of it in stock awards, but his stock payout for this year will be cut.

7 days ago

Photo: Players and staff on the Utah bench react toward the end of a second-round college basketbal...

Associated Press

Police say use of racial slur clearly audible as they investigate racist incidents toward Utah team

Police say they've found an audio recording in which the use of a racial slur directed toward the Utah basketball team was clearly audible.

8 days ago

Photo: The Boeing Co. logo is displayed outside of company offices....

David Koenig, The Associated Press

Boeing pays Alaska Airlines $160 million in compensation for blowout of panel during flight

Alaska Airlines said Boeing has paid the carrier $160 million in "initial compensation" for a panel that blew out of a Boeing 737 Max 9.

8 days ago

Alzheimer’s drug shows promise in early results of study